S809 A Higher Induction Dosing Regimen of Adalimumab Does Not Enhance Modulation of Downstream Blood Molecular Markers in Patients With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis. (October 2021) - Ferrante, Marc; Pivorunas, Valerie; Butler, James; Mahi, Naim; Mostafa, Nael; Ruzek, Melanie; Fann, James; Hong, Feng; Cao, Xiaohong; Smaoui, Nizar; Davis, Justin Wade; Kalabic, Jasmina; et al.